compared to placebo and was increased to a greater extent in patients receiving BM + T/O 5/5 µg + ExT compared to placebo at 8 weeks. EET was not significantly increased in patients receiving BM + T 5 µg compared to placebo (Table). Similar increases in EET were demonstrated at 12 weeks (Table). 13 patients reached test termination criteria (20 minutes) without symptom limitation (placebo, n=0; T, n=3; T/O, n=2; T/O + ExT, n=8) at 8 weeks. No safety concerns were identified.

Conclusions When added to BM, the bronchodilator combination T/O 5/5 µg, used alone and combined with ExT, improved EET during ESWT compared to placebo in moderate to severe COPD.

Funding Boehringer Ingelheim.

Please refer to page A270 for declarations of interest in relation to abstract S34.

S35 EFFICACY AND SAFETY OF THE DIRECT SWITCH FROM VARIOUS PREVIOUS TREATMENTS TO GLYCOPYRRONIUM OR INDACATEROL/ GLYCOPYRRONIUM IN PATIENTS WITH MODERATE COPD: THE CRYSTAL STUDY

¹C Vogelmeier, ²M Aalamian-Mattheis, ¹T Greulich, ³J M Marin, ⁴W Castellani, ⁵T Similowski, ⁶V Ninane, ⁷M Gaga, ⁸S Lane, ⁹X Nunez, ²F Patalano, ²A Clemens, ²K Kostikas. ¹University Medical Centre Giessen and Marburg, Marburg, Germany; ²Novartis Pharma AG, Basel, Switzerland; ³Respiratory Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain; ⁴Department of Respiratory Physiopathology, Palagi Hospital, Florence, Italy; ⁵Respiratory Medicine and Intensive Care, Pitié – Salpêtrière Hospital, Paris, France; ⁶CHU Saint-Pierre – Service de Pneumologie, Brussels, Belgium; ⁷Athens Chest Hospital “Sotiria”, Athens, Greece; ⁸Adelaide and Meath Hospital, Dublin, Ireland; ⁹TFS Develop, Barcelona, Spain

10.1136/thoraxjnl-2016-209333.41

Introduction and objectives In contrast to clinical trials, changes to new therapies in clinical practice occur without any washout period. The CRYSTAL study was designed to mimic clinical practice. Patients with symptomatic, non-frequently exacerbating,

moderate COPD treated with various drugs were directly switched to glycopyrronium 50 µg (GLY) or indacaterol/glycopyrronium 110/50 µg (IND/GLY). Lung function and symptoms were evaluated.

Methods CRYSTAL was a prospective, multicentre, 12-week, randomised, pragmatic, open-label trial. Patients were recruited into 4 Groups according to previous medication and symptoms (mMRC) and randomised to a direct switch to GLY or IND/GLY vs. continuation of baseline therapy (3:1). Co-primary objectives were superiority of GLY vs. previous SABA and/or SAMA, non-inferiority of GLY vs. previous LABA or LAMA, and superiority of IND/GLY vs. LABA, LAMA and LABA+ICS regarding trough FEV1 and transition dyspnoea index (TDI) at Week 12. Due to slow recruitment, Groups A and B were prematurely discontinued at the time of completion of Groups C and D.

Results Of the 4,389 patients randomised, 2,159 patients received IND/GLY (C2: n = 811; D2: n = 811) or continued their previous treatment (LABA + ICS C1: n = 269; LABA or LAMA D1: n = 268). IND/GLY provided superior improvement in trough FEV1 at Week 12 vs. LABA + ICS (treatment difference (Δ) = 71 mL, p < 0.0001) and LABA or LAMA (Δ = 101 mL, p < 0.0001). IND/GLY also improved TDI vs. LABA + ICS (Δ = 1.10 units, p < 0.0001) and vs. LABA or LAMA (Δ = 1.26 units, p < 0.0001). Significantly more patients on IND/GLY reached the minimally clinically important difference (MCID) of 100 mL for trough FEV1 and 1 point for TDI vs. comparators (Table 1). In the Groups A and B that were underpowered due to sample size, GLY was superior to previous SABA and/or SAMA and was non-inferior to previous LABA or LAMA on trough FEV1 and TDI (Table 1). GLY and IND/GLY were well tolerated.

Conclusions In the pragmatic CRYSTAL trial, IND/GLY demonstrated superior improvement in lung function (trough FEV1) and dyspnoea (TDI) after 12 weeks, in symptomatic patients with moderate COPD and a history of up to 1 exacerbation in the previous year, after direct switch from previous treatment with either LABA+ICS or with a LABA or LAMA.

Abstract S35 Table 1 CRYSTAL Study Results

	A1 (n = 122)	A2 (n = 369)	B1 (n = 420)	B2 (n = 1254)	C1 (n = 269)	C2 (n = 811)	D1 (n = 268)	D2 (n = 811)
Trough FEV ₁ (L)	1.826 [1.780, 1.873]	1.892 [1.865, 1.919]	1.800 [1.777, 1.824]	1.822 [1.808, 1.835]	1.685 [1.654, 1.715]	1.756 [1.738, 1.774]	1.673 [1.646, 1.699]	1.774 [1.759, 1.790]
Differences in trough FEV ₁ (L)	0.065 [0.011, 0.119]*		0.021 [−0.006, 0.048] [#]		0.071 [0.036, 0.107]**		0.101 [0.071, 0.132]**	
Patients with MCID in trough FEV ₁ (≥ 100 mL) [†]	1.770 (1.150, 2.724)	1.401	1.401 (1.092, 1.798)		1.902 (1.421, 2.546)		2.526 (1.863, 3.424)	
TDI	0.51 [−0.01, 1.03]	2.30 [2.00, 2.60]	0.70 [0.42, 0.98]	1.44 [1.27, 1.60]	0.90 [0.47, 1.23]	1.95 [1.72, 2.18]	0.90 [0.51, 1.22]	2.12 [1.91, 2.33]
Differences in TDI	1.79 [1.19, 2.39]**		0.74 [0.41, 1.06] [#]		1.10 [0.652, 1.55]**		1.26 [0.848, 1.67]**	
Patients with MCID in TDI (≥ 1 point) [†]	4.58 [2.86, 7.34]		2.57 [2.00, 3.29]		2.609 [1.94, 3.50]		2.853 [2.13, 3.82]	

All data are LSM Data with [95% CI], unless otherwise stated

[†]Odds ratios are displayed with [95% CI]

Linear mixed model. All primary efficacy analysis are superiority analysis except B1-B2 which are non-inferiority analysis.

Group B: non-inferiority testing (Δ: −40mL for trough FEV₁ and −0.6 points for TDI)

* p < 0.05; ** p < 0.0001; [#]p < 0.0001 (non-inferiority)

A1 (any SABA and/or SAMA), A2 (GLY), B1 (any LABA or LABA and mMRC = 1), B2 (GLY and mMRC = 1)

C1 (any LABA and ICS), C2 (IND/GLY), D1 (any LABA or LABA and mMRC > 1), D2 (IND/GLY and mMRC > 1)

CI: confidence intervals; LSM: least square means; OR: odds ratio; MCID, minimal clinically important difference